Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
URGN 
UroGen Pharma Ltd (URGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/13/2025: URGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $35.25
1 Year Target Price $35.25
| 5 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.26% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.12B USD | Price to earnings Ratio - | 1Y Target Price 35.25 |
Price to earnings Ratio - | 1Y Target Price 35.25 | ||
Volume (30-day avg) 8 | Beta 1.26 | 52 Weeks Range 3.42 - 25.19 | Updated Date 11/14/2025 |
52 Weeks Range 3.42 - 25.19 | Updated Date 11/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.47 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-17 | When - | Estimate -0.6434 | Actual -0.69 |
Profitability
Profit Margin -170.59% | Operating Margin (TTM) -99.65% |
Management Effectiveness
Return on Assets (TTM) -33.96% | Return on Equity (TTM) -1481.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1178094544 | Price to Sales(TTM) 11.6 |
Enterprise Value 1178094544 | Price to Sales(TTM) 11.6 | ||
Enterprise Value to Revenue 12.21 | Enterprise Value to EBITDA -2.63 | Shares Outstanding 46808892 | Shares Floating 39905517 |
Shares Outstanding 46808892 | Shares Floating 39905517 | ||
Percent Insiders 6.79 | Percent Institutions 96.48 |
Upturn AI SWOT
UroGen Pharma Ltd
Company Overview
History and Background
UroGen Pharma Ltd. is a biopharmaceutical company founded in 2004, focusing on developing and commercializing novel solutions to treat specialty cancers and urothelial diseases. It went public in 2017. Significant milestones include the FDA approval of Jelmyto and the continued development of its pipeline.
Core Business Areas
- Oncology: Focuses on developing and commercializing therapies for urothelial cancers, including non-muscle invasive bladder cancer (NMIBC).
Leadership and Structure
Liz Barrett is the President and CEO. The company has a board of directors and operates with functional departments including R&D, Commercial, and Operations.
Top Products and Market Share
Key Offerings
- Jelmyto (mitomycin gel): Jelmyto is a non-surgical treatment for low-grade upper tract urothelial cancer (LG-UTUC). Jelmyto's revenue was $93.4 million in 2023. Competitors include surgery and Bacillus Calmette-Guu00e9rin (BCG) intravesical therapy.
Market Dynamics
Industry Overview
The urothelial cancer treatment market is growing due to the aging population and increasing incidence of bladder cancer. The market includes surgical procedures, chemotherapy, and targeted therapies.
Positioning
UroGen is positioned as an innovator in the NMIBC space with its non-surgical Jelmyto treatment, offering an alternative to invasive procedures. The company's advantage lies in its targeted drug delivery technology.
Total Addressable Market (TAM)
The TAM for NMIBC treatment is estimated to be billions of dollars. UroGen is positioned to capture a significant portion of this market with Jelmyto and future pipeline products.
Upturn SWOT Analysis
Strengths
- FDA-approved product (Jelmyto)
- Novel drug delivery technology
- Strong intellectual property protection
Weaknesses
- Reliance on a single product (Jelmyto)
- Limited commercial infrastructure
- High R&D expenses
Opportunities
- Expansion of Jelmyto label to other indications
- Development of new pipeline products
- Partnerships and collaborations
Threats
- Competition from existing and emerging therapies
- Regulatory hurdles
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- BMY
Competitive Landscape
UroGen's advantage lies in its novel, non-surgical approach. However, it faces competition from established pharmaceutical companies with broader product portfolios and larger commercial infrastructure. UroGen competes directly with existing bladder cancer treatments.
Growth Trajectory and Initiatives
Historical Growth: UroGen has experienced growth driven by the commercialization of Jelmyto. Revenue has increased steadily since its launch.
Future Projections: Analysts project continued revenue growth for Jelmyto and potential upside from pipeline development. The company aims to expand its product portfolio and market reach.
Recent Initiatives: Recent initiatives include expanding the commercial team, conducting clinical trials for new indications, and seeking partnerships to accelerate growth.
Summary
UroGen Pharma has a novel product Jelmyto, which has shown strong initial adoption. The company is currently not profitable and has high R&D spend, but is seeing revenue growth. They face competition from larger pharma companies. It will need to continue driving Jelmyto sales and advancing its pipeline to achieve sustainable growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- UroGen Pharma Ltd. Investor Relations
- Company SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About UroGen Pharma Ltd
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2017-05-04 | President, CEO & Director Ms. Elizabeth A. Barrett | ||
Sector Healthcare | Industry Biotechnology | Full time employees 287 | Website https://www.urogen.com |
Full time employees 287 | Website https://www.urogen.com | ||
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.